Special attention is required in planning and administering radiation therapy to patients with cardiac implantable electronic devices (CIEDs), such as pacemaker and defibrillator. The range of dose to CIEDs that can induce malfunction is large among CIEDs. Clinically significant defects have been reported at dose as low as 0.15 Gy.
| INTRODUCTION
As the average life span of the world population grows, there is also an increase in the use of cardiac implantable electronic devices (CIEDs), including pacemakers and defibrillators, to maintain normal cardiac function in aged humans. This increased CIED use can be seen in data that show the use of pacemakers growing by 55.6% from 1993 to 2009. 1 These devices prove beneficial to cardiac health, but they add limitations to radiation therapy given the pulse generator's inability to tolerate certain levels of radiation dose. The likelihoods of having a dependency on a CIED and contracting cancer are both tied to aging. 2 The dose limitation added by the presence of a pacemaker near a tumor during radiation treatment is a growing problem. There is a need to find innovative and simple ways to lower and more accurately estimate the dose delivered to the CIEDs.
Mouton et al 3 observed that varying levels of dose can cause parasitic signal, alter the properties of semiconductor materials, and even cause permanent silence within CIEDs. Some of these problems are temporary, i.e., after radiation treatment, the CIED can return to its normal operation. The permanent silence failure causes the pulse generator to permanently cease operation. AAPM TG34 report 4 recommends the total accumulative dose received by pacemakers to be less than 2 Gy. Since the publication of AAPM TG34 report, cardioverter defibrillators have also been widely used. Medtronic provides 1-5 Gy dose limits to their defibrillators for different models.
Other vendors did not provide an explicit safe limit for their devices.
Therefore, many clinics limit the defibrillator dose to less than 1 Gy in the absence of a specific recommendation from device manufacturer. However, Mouton and colleagues 3 observed that clinically important defects could occur at doses as low as 15 cGy and faults that cause discomfort could occur at doses as low as 5 cGy. They noted that even temporary CIED failures, triggered at lower dose, could create health risks. The more recently published Netherland guideline 5 gives extra attention to pacing dependent patients. Even if the CIED dose is less than 2 Gy, those patients are still considered at medium risk instead of low because CIED malfunction is especially deleterious; therefore, the guidelines for medium risk should be followed. 5 With technology improvements, the average size of pacemakers has decreased. This has caused pacemakers to become more susceptible to damage caused by radiation. 6 The "increased circuit complexity, the ever-decreasing power consumption, and possibly the decreased dose attenuation of the CIED case" also contribute to the radiosensitivity. 5 It has been recommended to know specific pacemaker make and model and the manufacturer's guidelines when planning radiation treatment near patient pacemakers. 7 Hurkmans et al 5 provided a comprehensive review on the topic of managing radiation oncology patients with CIEDs. We will briefly summarize some new papers after the publication of that review.
Treatment plans involving patients with CIEDs should keep the pacemaker out of the direct beam 4 and use less than 10-MV beams. 8 Many clinics, including ours, consider 6 MV as optimal for CIED patients and eliminate the use of high photon energy for those patients. This is because neutrons produced in high-energy beams are believed to be the main cause of CIED defects. 5 The dose to CIED should reduce the dose to CIEDs from anterior beams. For posterior beams, backscatter from the bolus to pacemaker should be less than that from the high-Z lead foil. When estimating dose to pacemaker, the dose measured by dosimeters under bolus should reflect more accurately the pacemaker dose compared to placing the dosimeters on the skin surface without covering it with bolus. We conducted phantom and patient measurements with and without bolus and using bolus only and bolus covered with lead to test this method.
| MATERIALS AND METHODS
Out-of-field dose was measured with a Markus parallel plate chamber at depths varying by 0.5-cm intervals between 0 and 3 cm in a solid water phantom for a 6 MV beam (Varian 2300IX). For each of these depths, measurements were conducted at distances of 2, 3, and 5 cm from the beam field edge. Figure 1 illustrates the experimental setup of the phantom measurements. A parallel plate chamber was used because it is suitable for measuring dose at surface/ build-up region in photon beams due to their thin entrance window and depth positioning accuracy. 10 The treatment plan was one AP field set to deliver 300 cGy at d max with 100 cm source-to-surface distance (SSD). Measurements were performed with and without bolus at three field sizes (5 9 5 cm, 10 9 10 cm, and 15 9 15 cm) and two collimator angles (0°and 90°). For 10 9 10 cm field and collimator 90°, measurements were performed without bolus, with 1-cm bolus, with 2 mm lead on top of 1-cm bolus, and with 2-cm bolus covering the chamber. These measurements were repeated on three different days to evaluate measurement uncertainty. To establish the conversion of ionization to dose, 100 MU was delivered at 100 SSD, 10 9 10 cm field with the chamber placed at d max in the solid water phantom. The dose in this condition is 100 cGy based on machine calibration. Chamber reading was converted to dose accordingly. Eclipse Analytical Anisotropic Algorithm (AAA) v13.6
was used to calculate dose values to be compared with the measured dose. The calculated dose is a volume average of a structure with 5.3 mm diameter on a single 2-mm CT slice, which corresponds to the Markus chamber dimension.
In vivo dose measurements were also conducted for three patients treated with 3D conformal 6 MV beams using OSLDs (nanoDot TM , Landauer) placed on the skin above the CIED. Two beams were used for two patients and three for the other patient. Beam directions are listed in Table 1 . According to the manufacturer, the accuracy of screened nanoDot is AE5.5%. Trials were performed on different treatment days in order to measure doses without bolus and with 1-or 2-cm bolus covering the OSLDs. With bolus, the measurements were conducted with and without 2 mm lead foil on top of the bolus. The measurement situations were slightly different for each patient as listed in Table 1 .
The pacemakers were within 5 cm to the closest treatment field edge. Figure 2 shows the setup of patient measurements. Two
OSLDs were placed on the skin surface, one at a location above the pacemaker near to the closest anterior treatment field edge (OSLD_A in Fig. 2) , and the other one approximately above the center or the distal portion of the pacemaker (OSLD_B in Fig. 2 ). The benefits of using a bolus to reduce dose to a CIED diminish if the CIED is located deeper than 1.5-2 cm, as it can be seen in Fig. 3(d) that the percent dose reduction at larger depth becomes insignificant. Figure 4 shows the measured and Eclipse calculated doses with and without 2-cm bolus for 10 9 10 cm field with collimator angles at 0°and 90°(setup as Fig. 1 ), as well as the percent difference in the measured dose with and without bolus. The measured out-of-field near surface dose is larger for 0°collimator. A reasonable explanation is that the x jaw is the lower jaw on Varian machines; therefore, at 0°, more collimator scatter can reach the chamber in the setup shown in Fig. 1 . The percent reductions are slightly more for 90°F
3.A.2 | Measurement at different collimator angles
I G . 1. Schematic illustration of the "out-of-field" dose measurement in solid water phantom.
T A B L E 1 Measured and calculated dose data for different patients. Fig. 2 .
Setup of the in vivo measurements of the pacemaker dose. The blue contour shows 1-cm bolus. The CIED is about 1 cm below the skin surface. provide similar amount of dose reduction for the depth more than 1 cm. However, for depth less than 1 cm, using 2 cm yields slightly more dose reduction than using 1-cm bolus.
3.A.3 | Measurement with different bolus thickness

3.B | Patient data
In vivo measurements and plan calculated results for the three patients are listed in Table 1 whether in vivo dose measurement is needed and whether additional checkup of the CIED and ECG monitoring during treatment are needed. 4, 5 It is convenient to estimate the dose using TPSs. However, TPSs are not commissioned for out-of-field dose calculation; therefore, the estimation accuracy is significantly limited, as can be seen from the differences between the Eclipse calculated doses and the measured doses shown in Table 1 . It should be noted that, in addition to the inaccuracies in the TPS algorithm, the differences can also be CIED. This is because the large uncertainty happens only near the surface, and the dose gradient is not steep at deeper regions. In addition, the bolus' shielding effect also reduces the dose to CIED.
We, therefore, recommend using bolus to cover CIED at all treatment fractions unless the CT scan shows that the entire CIED is >2 cm deep in the body. In that case, Fig. 3 shows that adding bolus as shielding may not be necessary as the dosimetric difference is small. However, this is not normally seen for modern CIEDs. In addition, when performing in vivo dosimetry, adding bolus is still useful in estimating more accurately the actual dose to CIED.
Another important consideration is the treatment beam configuration. It is more effective to use bolus if the dose contribution from the anterior beams is much larger than that from the posterior beams. In fact, for posterior beams, adding a lead shield can slightly increase the backscatter to the CIED. 9 Backscatter can also be expected for bolus, but to a lesser extent compared to the high-Z material. Table 1 , it is noticed that the TPS calculated doses are reasonably in agreement with the measured dose with the presence of bolus. For example, this can be seen from Table 1 by comparing the measured dose under bolus to the calculated dose inside the CIED. It suggests that the use of a bolus on patients can not only serve to lower the dose to the CIED, but also prove to be beneficial to allow the use of the TPS to more accurately estimate the CIED dose prior to treatment.
| CONCLUSIONS
In vivo CIED dose measurements with the bolus covering dosimeter on the skin above the CIED reflect more accurately the delivered dose to the CIED. Phantom measurements and patient in vivo dosimetry show that covering the CIED with 1-to 2-cm bolus during radiotherapy can substantially reduce the dose to CIED if the CIED is implanted at very shallow depths (<2 cm below skin surface) and most CIED dose is from anterior radiation beams. Adding the bolus also helps the TPS to more accurately predict the CIED dose prior to treatment for well-informed patient management decision.
We recommend the use of bolus to cover the CIED during radiotherapy.
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